Mesenchymal stem cells as novel micro-ribonucleic acid delivery vehicles in kidney disease

Kevin Yao, Sharon D Ricardo

Research output: Contribution to journalArticleResearchpeer-review

Abstract

MicroRNAs (miRNAs) are short single strands of RNA responsible for post-transcriptional regulation of gene expression and have been implicated in the pathogenesis of chronic kidney disease (CKD). Emerging evidence reports that miRNAs can reduce kidney fibrosis through regulation of targets associated with collagen and extracellular matrix accumulation. However, the development of miRNA therapies has been hampered by the lack of targeted and sustainable methods of systemic miRNA delivery. Mesenchymal stem cells (MSCs) provide a promising miRNA delivery platform to overcome toxicity, the potential for insertional mutations, and the low efficiency of previous methods. MSCs are endogenously immunoprivileged and home to sites of inflammation. They also release trophic growth factors to modulate the immune system, alter the polarisation of macrophages, and provide renal protection and repair. The potential to engineer MSCs to express or overexpress miRNAs, released by exosomes, may enhance their natural functions. Clinical studies are already being conducted individually for the use of miRNAs in cancer and MSCs in diseases associated with CKD. Hence, the combination of miRNAs and MSCs may provide an unparalleled cell-based therapy for treating CKD. This article is protected by copyright. All rights reserved.
Original languageEnglish
Pages (from-to)363-371
Number of pages9
JournalNephrology
Volume21
Issue number5
DOIs
Publication statusPublished - 1 May 2016

Keywords

  • exosome
  • kidney fibrosis
  • mesenchymal stem cells
  • miRNA

Cite this

@article{8ee31c2100d34407bdf080ae8416febd,
title = "Mesenchymal stem cells as novel micro-ribonucleic acid delivery vehicles in kidney disease",
abstract = "MicroRNAs (miRNAs) are short single strands of RNA responsible for post-transcriptional regulation of gene expression and have been implicated in the pathogenesis of chronic kidney disease (CKD). Emerging evidence reports that miRNAs can reduce kidney fibrosis through regulation of targets associated with collagen and extracellular matrix accumulation. However, the development of miRNA therapies has been hampered by the lack of targeted and sustainable methods of systemic miRNA delivery. Mesenchymal stem cells (MSCs) provide a promising miRNA delivery platform to overcome toxicity, the potential for insertional mutations, and the low efficiency of previous methods. MSCs are endogenously immunoprivileged and home to sites of inflammation. They also release trophic growth factors to modulate the immune system, alter the polarisation of macrophages, and provide renal protection and repair. The potential to engineer MSCs to express or overexpress miRNAs, released by exosomes, may enhance their natural functions. Clinical studies are already being conducted individually for the use of miRNAs in cancer and MSCs in diseases associated with CKD. Hence, the combination of miRNAs and MSCs may provide an unparalleled cell-based therapy for treating CKD. This article is protected by copyright. All rights reserved.",
keywords = "exosome, kidney fibrosis, mesenchymal stem cells, miRNA",
author = "Kevin Yao and Ricardo, {Sharon D}",
year = "2016",
month = "5",
day = "1",
doi = "10.1111/nep.12643",
language = "English",
volume = "21",
pages = "363--371",
journal = "Nephrology",
issn = "1320-5358",
publisher = "Wiley-Blackwell",
number = "5",

}

Mesenchymal stem cells as novel micro-ribonucleic acid delivery vehicles in kidney disease. / Yao, Kevin; Ricardo, Sharon D.

In: Nephrology, Vol. 21, No. 5, 01.05.2016, p. 363-371.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Mesenchymal stem cells as novel micro-ribonucleic acid delivery vehicles in kidney disease

AU - Yao, Kevin

AU - Ricardo, Sharon D

PY - 2016/5/1

Y1 - 2016/5/1

N2 - MicroRNAs (miRNAs) are short single strands of RNA responsible for post-transcriptional regulation of gene expression and have been implicated in the pathogenesis of chronic kidney disease (CKD). Emerging evidence reports that miRNAs can reduce kidney fibrosis through regulation of targets associated with collagen and extracellular matrix accumulation. However, the development of miRNA therapies has been hampered by the lack of targeted and sustainable methods of systemic miRNA delivery. Mesenchymal stem cells (MSCs) provide a promising miRNA delivery platform to overcome toxicity, the potential for insertional mutations, and the low efficiency of previous methods. MSCs are endogenously immunoprivileged and home to sites of inflammation. They also release trophic growth factors to modulate the immune system, alter the polarisation of macrophages, and provide renal protection and repair. The potential to engineer MSCs to express or overexpress miRNAs, released by exosomes, may enhance their natural functions. Clinical studies are already being conducted individually for the use of miRNAs in cancer and MSCs in diseases associated with CKD. Hence, the combination of miRNAs and MSCs may provide an unparalleled cell-based therapy for treating CKD. This article is protected by copyright. All rights reserved.

AB - MicroRNAs (miRNAs) are short single strands of RNA responsible for post-transcriptional regulation of gene expression and have been implicated in the pathogenesis of chronic kidney disease (CKD). Emerging evidence reports that miRNAs can reduce kidney fibrosis through regulation of targets associated with collagen and extracellular matrix accumulation. However, the development of miRNA therapies has been hampered by the lack of targeted and sustainable methods of systemic miRNA delivery. Mesenchymal stem cells (MSCs) provide a promising miRNA delivery platform to overcome toxicity, the potential for insertional mutations, and the low efficiency of previous methods. MSCs are endogenously immunoprivileged and home to sites of inflammation. They also release trophic growth factors to modulate the immune system, alter the polarisation of macrophages, and provide renal protection and repair. The potential to engineer MSCs to express or overexpress miRNAs, released by exosomes, may enhance their natural functions. Clinical studies are already being conducted individually for the use of miRNAs in cancer and MSCs in diseases associated with CKD. Hence, the combination of miRNAs and MSCs may provide an unparalleled cell-based therapy for treating CKD. This article is protected by copyright. All rights reserved.

KW - exosome

KW - kidney fibrosis

KW - mesenchymal stem cells

KW - miRNA

UR - http://www.ncbi.nlm.nih.gov/pubmed/26437381

U2 - 10.1111/nep.12643

DO - 10.1111/nep.12643

M3 - Article

VL - 21

SP - 363

EP - 371

JO - Nephrology

JF - Nephrology

SN - 1320-5358

IS - 5

ER -